Treatment of steroid-naive ulcerative colitis
Authors:
- Fabrizio BossaFBFabrizio Bossa
- Elisabetta ColomboECElisabetta Colombo
- Angelo AndriulliAAAngelo Andriulli
- Vito AnneseVAVito Annese
- 15 May 2009
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 10 (9) , 1449-1460
Abstract
The introduction of steroid therapy by Truelove and Witts in the 1950s revolutionized the treatment of ulcerative colitis. Corticosteroids are potent inhibitors of T-cell activation and proinflammatory cytokines and still represent the mainstay of therapy of patients with ulcerative colitis. About 15% of patients are resistant to steroids, and about a quarter of patients become dependent within 1 year of therapy. Steroid-related adverse events are numerous and occur frequently. So, new steroids with low systemic absorption and better safety profile have been studied, but they show an overall lower efficacy compared with traditional steroids. A new drug-delivery system based on the use of autologous erythrocytes loaded with dexamethasone 21-phosphate has been recently developed. Several studies have demonstrated its efficacy in steroid-dependent patients leading to complete withdrawal of oral steroids and disappearance of the most steroid-related adverse events. In this review we elaborate on the role of steroids in the treatment of ulcerative colitis, focusing on the aspects related to the mechanisms of action and resistance to the steroids, and their secondary effects. Moreover, we analyse the alternatives to traditional systemic steroids such as the new steroids with low bioavailability and the steroids encapsulated into erythrocytes.Keywords
This publication has 96 references indexed in Scilit:
- Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based CohortGastroenterology, 2007
- Long‐term Treatment With Autologous Red Blood Cells Loaded With Dexamethasone 21–Phosphate in Pediatric Patients Affected by Steroid‐dependent Crohn DiseaseJournal of Pediatric Gastroenterology and Nutrition, 2007
- The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5‐year UK inception cohortAlimentary Pharmacology & Therapeutics, 2006
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- Multidrug resistance 1 gene polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patientsAlimentary Pharmacology & Therapeutics, 2005
- Pharmacokinetics of Budesonide (Entocort??? EC) Capsules for Crohn???s DiseaseClinical Pharmacokinetics, 2004
- Double blind trial of oral fluticasone propionate v prednisolone in the treatment of active ulcerative colitis.Gut, 1993
- A Controlled Randomized Trial of Budesonide versus Prednisolone Retention Enemas in Active Distal Ulcerative ColitisScandinavian Journal of Gastroenterology, 1987
- FURTHER EXPERIENCE IN THE TREATMENT OF SEVERE ATTACKS OF ULCERATIVE COLITISThe Lancet, 1978
- Out-patient Treatment of Ulcerative ColitisBMJ, 1962